💥 Fed cuts sparks mid cap boom! ProPicks AI scores with 4 stocks +23% each. Get October’s update first.Pick Stocks with AI

DaVita appoints new COO as Staffieri transitions

EditorLina Guerrero
Published 09/13/2024, 04:27 PM
DVA
-

DaVita Inc . (NYSE:DVA), a leading provider of kidney care services, announced the appointment of David P. Maughan as the new Chief Operating Officer of DaVita Kidney Care, effective September 15, 2024. Maughan succeeds Michael D. Staffieri, who will take on the role of Chief Operating Officer Emeritus from the same date.


Maughan, 47, has a long tenure with DaVita, having joined the company in 2006. He has climbed through various operational roles and most recently held the position of Senior Vice President, where he was responsible for home and hospital services, as well as overseeing human resources, IT, marketing, communications, and state government affairs.


His prior experience includes working in finance for Goldman Sachs in New York City and London. Maughan is a Harvard Business School MBA graduate and holds an undergraduate degree in English literature from Brigham Young University.


The transition comes with a new employment agreement for Maughan, which includes an annual base salary of $725,000 and eligibility for a target incentive bonus equal to 100% of his base salary for 2024. He will also participate in the company's employee benefit plans and long-term cash or equity incentive plans.


In the event of termination without material cause or if Maughan resigns for good cause, he will be entitled to benefits under the DaVita Inc. Severance Plan for Directors and Above, subject to certain conditions.


In other recent news, DaVita Inc. has made several notable developments. The company outperformed Q2 2024 expectations with an adjusted operating income of $506 million and adjusted earnings per share of $2.59. These strong results have been attributed to strategic initiatives aimed at addressing the nursing shortage and improving revenue per treatment.


In a significant financial move, DaVita's Board approved an additional $2 billion authorization for its existing share repurchase program. The company also announced the appointment of David Maughan as the new chief operating officer. Maughan, who has been with DaVita for 18 years, will succeed Mike Staffieri, who will transition to the role of chief operating officer emeritus.


Truist Securities revised its earnings estimates for DaVita upward, now projecting the company to achieve an adjusted earnings per share of $9.72 in 2024, up from the previous estimate of $9.46. For 2025, the forecast has been raised to an adjusted EPS of $11.06, compared to the earlier prediction of $10.42, reflecting a positive outlook for DaVita's future financial performance.


InvestingPro Insights


As DaVita Inc. (NYSE:DVA) welcomes David P. Maughan into his new role as Chief Operating Officer, the company's financial health and market performance offer valuable context for stakeholders. DaVita has been actively enhancing shareholder value, with management aggressively buying back shares, signaling confidence in the company's future. Analysts have also taken a positive view, with three analysts revising their earnings upwards for the upcoming period, reflecting optimism about DaVita's operational efficiency and growth prospects.


From a valuation standpoint, DaVita is trading at a low P/E ratio relative to near-term earnings growth, currently standing at 16.87. This suggests that the stock could be undervalued considering its growth potential. Moreover, the company's valuation implies a robust free cash flow yield, which is a strong indicator of financial health and the ability to invest in future growth or return capital to shareholders.


In the last twelve months as of Q2 2024, DaVita has shown a revenue growth of 6.69%, demonstrating its ability to expand its top-line figures. The company's profitability is further underscored by a solid operating income margin of 14.76%, reflecting efficient management and a strong position within the Healthcare Providers & Services industry. Investors may also find reassurance in DaVita's consistent performance, with the stock trading near its 52-week high and delivering a high return over the last year.


For those interested in deeper analysis and additional insights, there are more InvestingPro Tips available for DaVita at Investing.com. This includes a comprehensive list of metrics and expert commentary that can inform investment decisions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.